logo

For the Inventor, By the Inventor

Hyogo, Japan

Shoji Fukumoto

This inventor holds 17 USPTO granted patents and 2 EPO patents, primarily in Heterocyclic Compounds. Top assignees: Takeda Pharmaceutical Company Limited, Takeda Chemical Industries, Inc.. Active years: 1992-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shoji Fukumoto. Retrieved from https://idiyas.com/inventor/shoji-fukumoto

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 17

% Patents Active = 47.1


Average Co-Inventor Count = 5.6

ph-index = 4

Forward Citations = 55(Granted Patents)


Location History:

  • Osaka, JP (2010)
  • Kanagawa, JP (2016)
  • Hyoto, JP (2017)
  • Hyogo, JP (2016 - 2018)
  • Kobe, JP (1992 - 2023)

Company Filing History:

goldMedal12 out of 1,229 
 
Takeda Pharmaceutical Company Limited
 patents
silverMedal5 out of 1,858 
 
Takeda Chemical Industries, Inc.
 patents

Years Active: 1992-2023

Loading Chart...
Loading Chart...
Areas of Expertise:
Heterocyclic Compounds
Amide Compounds
ROR Inhibitors
Sulfonamide Derivatives
Pyrazoloquinolone
Nasal Preparations
Aminoguanidine
Optically Active Phenols
Nitrosothiol Derivatives
Medicinal Chemistry
Drug Development
17 patents (USPTO):Explore Patents
1. 11851449 - Heterocyclic amide compounds having an RORvt inhibitory action (2023-12-26),
2. 11053262 - Heterocyclic amide compounds having RORyT inhibitory action (2021-07-06),
3. 10472376 - Amide compound (2019-11-12),
4. 10093629 - Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors (2018-10-09),
5. 10053468 - Heterocyclic compound (2018-08-21),
6. 10000488 - Heterocyclic compound (2018-06-19),
7. 9650343 - Heterocyclic compound (2017-05-16),
8. 9630924 - Heterocyclic compound (2017-04-25),
9. 9573903 - Heterocyclic compound (2017-02-21),
10. 9527807 - Sulfonamide derivative and use thereof (2016-12-27),
11. 9365520 - Heterocyclic compound (2016-06-14),
12. 7842701 - Pyrazoloquinolone derivative and use thereof (2010-11-30),
13. 6706732 - Nasal preparation of guanidinoimino quinoline derivatives (2004-03-16),
14. 6350749 - Aminoguanidine hydrazone derivatives, process for producing the same and drugs thereof (2002-02-26),
15. 5420363 - Optically active phenol derivatives and preparation thereof (1995-05-30),

Title: The Innovations of Shoji Fukumoto

Introduction

Shoji Fukumoto is a prominent inventor based in Hyogo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of heterocyclic amide compounds. With a total of 17 patents to his name, Fukumoto's work has had a considerable impact on medical research and drug development.

Latest Patents

Fukumoto's latest patents include innovative compounds that exhibit RORγt inhibitory action. The first patent describes a compound (I) or a salt thereof that has a specific RORγt inhibitory action, with detailed specifications provided for each symbol in the formula. The second patent also focuses on heterocyclic amide compounds with RORγt inhibitory action, further emphasizing the potential therapeutic applications of these compounds.

Career Highlights

Throughout his career, Fukumoto has worked with notable companies in the pharmaceutical industry. He has been associated with Takeda Pharmaceutical Company Limited and Takeda Chemical Industries, Inc., where he has contributed to various research and development projects. His expertise in medicinal chemistry has been instrumental in advancing drug discovery efforts.

Collaborations

Fukumoto has collaborated with several esteemed colleagues, including Satoshi Yamamoto and Junya Shirai. These collaborations have fostered a productive environment for innovation and have led to the successful development of new pharmaceutical compounds.

Conclusion

Shoji Fukumoto's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a key innovator. His work continues to influence the development of new therapeutic agents, showcasing the importance of innovation in the medical field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…